Alector Past Earnings Performance
Past criteria checks 0/6
Alector's earnings have been declining at an average annual rate of -0.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 18.5% per year.
Key information
-0.9%
Earnings growth rate
6.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 18.5% |
| Return on equity | -133.2% |
| Net Margin | -257.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry
Oct 24
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully
Sep 26Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking
Jul 11Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Mar 01The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%
Jan 19Alector: Good Data, Huge Cash, No Near Term Catalyst
Jan 16Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Sep 25Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Jun 27Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week
Mar 02Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans
Jan 16Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
Oct 04AbbVie ends partnership with Alector for Alzheimer’s candidate
Jul 08Alector: Potential In Neurology And Cancer Treatments
Jun 14Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022
May 18Alector: Expect Phase 3 Data Next Year
Apr 16These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts
Feb 27Alector, Inc: A Newer Biotech Company With Big Potential
Jan 26Revenue & Expenses Breakdown
How Alector makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 62 | -158 | 57 | 0 |
| 30 Jun 24 | 55 | -161 | 57 | -6 |
| 31 Mar 24 | 96 | -121 | 56 | 0 |
| 31 Dec 23 | 97 | -130 | 57 | 0 |
| 30 Sep 23 | 96 | -141 | 57 | 0 |
| 30 Jun 23 | 102 | -143 | 58 | 87 |
| 31 Mar 23 | 126 | -135 | 60 | 0 |
| 31 Dec 22 | 134 | -133 | 61 | 0 |
| 30 Sep 22 | 133 | -136 | 63 | 0 |
| 30 Jun 22 | 301 | 36 | 61 | 0 |
| 31 Mar 22 | 227 | -29 | 60 | 0 |
| 31 Dec 21 | 207 | -36 | 55 | 0 |
| 30 Sep 21 | 198 | -33 | 51 | 0 |
| 30 Jun 21 | 21 | -212 | 54 | 0 |
| 31 Mar 21 | 18 | -202 | 56 | 0 |
| 31 Dec 20 | 21 | -190 | 59 | 0 |
| 30 Sep 20 | 22 | -169 | 58 | 0 |
| 30 Jun 20 | 19 | -148 | 51 | 0 |
| 31 Mar 20 | 23 | -127 | 43 | 0 |
| 31 Dec 19 | 21 | -105 | 34 | 0 |
| 30 Sep 19 | 24 | -92 | 27 | 0 |
| 30 Jun 19 | 28 | -76 | 20 | 0 |
| 31 Mar 19 | 28 | -62 | 15 | 0 |
| 31 Dec 18 | 28 | -52 | 12 | 0 |
| 30 Sep 18 | 22 | -45 | 10 | 0 |
| 30 Jun 18 | 15 | -39 | 9 | 0 |
| 31 Mar 18 | 8 | -35 | 8 | 0 |
| 31 Dec 17 | 4 | -32 | 7 | 0 |
| 31 Dec 16 | 0 | -15 | 2 | 0 |
Quality Earnings: ALEC is currently unprofitable.
Growing Profit Margin: ALEC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALEC is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare ALEC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALEC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ALEC has a negative Return on Equity (-133.19%), as it is currently unprofitable.